Regulus Therapeutics, a microRNA-focused drug developer, has added to its impressive roster of pharmaceutical partners by signing a new deal with AstraZeneca.
Under the agreement, which covers three programmes focused on cardiovascular and metabolic diseases and oncology that are currently in preclinical...